▎ 摘　　要

The adsorption of doxorubicin (DOX), as anticancer drug, onto a microwave synthesized and loaded graphene oxide with 3-aminopropyltrimethoxysilane for the formation of a target drug nanocarrier (GO@3-APTMSi) was explored and investigated. GO@3-APTMSi was simply synthesized according to a facile microwave-assisted synthesis via irradiation heating. The particle size of GO@3-APTMSi nanocarrier was confirmed in the range 16.43-31.06 nm as determined by the TEM analysis. Other instrumental techniques as FT-IR, SEM/EDX, XRD zeta potential were implemented for the aim of structural and morphological characterizations. The doxorubicin (DOX) loading capacity on the surface of GO@3-APTMSi was confirmed as 92.6 %. The DOX drug binding process was established and interpreted on the basis of strong Schiff's base formation reaction between the carbonyl group in DOX molecule with the loaded amino groups on GO@3-APTMSi as well as hydrogen bonding and 7C-7C stacking mechanisms. The behavior of DOX release from DOX@GO@3-APTMSi nanocarrier was also investigated in two different buffering conditions, viz. pH 5.4 and 7.4 and the DOX release values after only 0.5 h were found to correspond to 87.1 % and 11.3 %, respectively. Moreover, the maximum percentage values for DOX release were characterized as 99.3-100.0 % at pH 5.4 using 6.0-7.0 h, while in pH 7.4, 94.3 % DOX release demanded 72.0 h. The DOX release from DOX@GO@3-APTMSi was also evaluated by using three different temperature values, viz. 37 degrees C, 47 degrees C and 57 degrees C and the collected results referred to the impact of incubation temperature in pH 7.4 and not in pH 5.4 as the DOX release provided 92.5-98.6 %, 93.9-99.3 % and 95.3-99.3 % (1.0-3.0 h) under the incubation temperatures 37 degrees C, 47 degrees C and 57 degrees C, respectively. According to the collected and outlined results and data in this work, one can conclude that the assembled GO@3-APTMSi may be listed as a promising and smart drug nanocarrier for applications in multi-modal cancer therapy via effective targeting of specific cancer tumor.